Canatu (CANATU) CMD 2024 summary

Strategic direction and transaction overview

• Announced a full share deal with Lifeline SPAC I, preserving up to €105.6 million in capital for future growth, with a €230 million valuation and up to €7 million in earn-outs tied to share price milestones.

• Secondary transaction of nearly €50 million brings in new institutional and tech investors, strengthening liquidity and investor base.

• Post-transaction, listing will transfer to First North Helsinki, with existing shareholders retaining 53%, Lifeline SPAC I shareholders 31%, and secondary tranche purchasers 16%.

• Board will include industry experts from semiconductors, automotive, and diagnostics, with ongoing support from the SPAC team.

• Key dates: Transaction announcement (5 July 2024), Capital Markets Day (20 August 2024), EGM (23 August 2024), and trading on First North Helsinki to begin September 17.

Technology and business model

• Focuses on advanced carbon nanotubes (CNTs) with proprietary dry deposition process, enabling high-performance, high-margin applications.

• Holds 130 patents and significant trade secrets, with mass production since 2015 in automotive and since 2021 in semiconductors.

• Business model includes direct product sales, reactor/equipment sales, and recurring revenue from royalties, licensing, and consumables.

• Platform technology allows rapid adaptation for different industries, targeting only high-value, high-margin segments.

• Joint R&D with lead customers is central, with customer-driven development in all business domains.

Market focus and growth plans

• Three core segments: semiconductors (~80% of 2023 revenue), automotive (~20%), and medical diagnostics (development phase).

• Semiconductor: EUV pellicles and inspection membranes for advanced chip manufacturing, with addressable market estimated at €1–2 billion by 2030.

• Automotive: Shift from touch sensors to ADAS camera and LiDAR heaters, with future potential in windshield heaters and solar cells; market opportunity up to €800 million by 2030.

• Medical diagnostics: Developing ultra-sensitive point-of-care test strips, with market potential of €400 million–€1 billion by 2030.

• Addressable markets in all segments expected to reach €2–4 billion by 2030, with double-digit growth rates.